Damora Therapeutics dismisses EY Denmark, engages Ernst & Young LLP as new auditor
On April 17, 2026, Damora Therapeutics' Audit Committee dismissed EY Denmark as its independent registered public accounting firm and engaged Ernst & Young LLP, effective immediately. The filing states there were no disagreements or reportable events with EY Denmark, but EY Denmark's report on the fiscal 2024 financial statements included a going concern explanatory paragraph.
Key points
- Dismissal and new engagement both dated April 17, 2026; EY Denmark had served as auditor since 2019.
- EY Denmark's reports for fiscal 2025 and 2024 had no adverse opinion or disclaimer; the 2024 report contained a going concern explanatory paragraph.
- The filing reports no disagreements or reportable events with EY Denmark during fiscal 2024, fiscal 2025 and the interim period through April 17, 2026.
- EY Denmark's letter to the SEC dated April 17, 2026 is filed as Exhibit 16.1.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.